Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)
15 avr. 2016 09h05 HE
|
Ocera Therapeutics, Inc.
Data establish ammonia-lowering properties of orally-administered OCR-002 in preclinical model of cirrhosisData highlight CNS neurochemical changes occurring in preclinical model of hepatic...
Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
11 avr. 2016 09h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 11, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at the 15th Annual Needham Healthcare Conference
05 avr. 2016 16h25 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 05, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
03 mars 2016 09h05 HE
|
Ocera Therapeutics, Inc.
-- Patient enrollment progressing in STOP-HE clinical trial of OCR-002; Company expects to complete enrollment in the fourth quarter of 2016 -- -- OCR-002 is the only ammonia scavenger in...
Ocera to Present at the Cowen and Company 36th Annual Health Care Conference
29 févr. 2016 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at the 18th Annual BIO CEO & Investor Conference
02 févr. 2016 16h20 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
08 janv. 2016 09h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer
07 janv. 2016 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
16 nov. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at Stifel 2015 Healthcare Conference
09 nov. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...